Loading clinical trials...
Loading clinical trials...
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity. How QGE031 is broken down by the body an...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06371417 · Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), and more
NCT02753777 · Pemphigus Vulgaris, Pemphigus Foliaceus, and more
NCT07188402 · Bullous Pemphigoid (BP)
NCT05984381 · Bullous Pemphigoid
NCT05906706 · Bullous Pemphigoid
Novartis Investigative Site
Iowa City, Iowa
Novartis Investigative Site
Durham, North Carolina
Novartis Investigative Site
Vienna
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions